Enhanced in vivo gene transfer into the placenta using RGD fiber-mutant adenovirus vector

Biomaterials

Volumn 32, Issue 17, 2011, Pages 4185-4193

  Katayama, Kazufumi ^a   Furuki, Rie ^a   Yokoyama, Hideaki ^a   Kaneko, Makoto ^a   Tachibana, Masashi ^a   Yoshida, Ichiro ^b   Nagase, Hisamitsu ^b   Tanaka, Keiichi ^c   Sakurai, Fuminori ^a   Mizuguchi, Hiroyuki ^a,d   Nakagawa, Shinsaku ^a   Nakanishi, Tsuyoshi ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA OHTANI UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Adenovirus; Drug delivery ; Gene expression; Gene transfer; RGD peptide

Indexed keywords

ADENOVIRUS; ADENOVIRUS VECTOR; ARG GLY ASPS; BASIC RESEARCH; FIREFLY LUCIFERASE; IN-VITRO; IN-VIVO; INTEGRINS; PEPTIDE SEQUENCES; PRECLINICAL STUDIES; RED FLUORESCENT PROTEINS; RGD PEPTIDE; TRANSDUCTION EFFICIENCY; TRANSGENE EXPRESSION; UNDIFFERENTIATED CELLS; VIRAL VECTORS;

DRUG DELIVERY; GENE THERAPY; GENE TRANSFER; PEPTIDES; STEM CELLS; VECTORS;

GENE EXPRESSION;

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; FEMALE; FETUS DEATH; GENE EXPRESSION; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLACENTA DISORDER; PRIORITY JOURNAL; TROPHOBLAST;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; CELLS, CULTURED; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTEGRIN ALPHAVBETA3; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGOPEPTIDES; PLACENTA; PREGNANCY; STEM CELLS; TRANSGENES; TROPHOBLASTS;

ADENOVIRIDAE; MUS;

EID: 79953277869     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.02.038     Document Type: Article

References (52)

1. Vorburger S.A., Hunt K.K. Adenoviral gene therapy. Oncologist 2002, 7:46-59.
2. Sakurai F., Kawabata K., Mizuguchi H. Adenovirus vectors composed of subgroup B adenoviruses. Curr Gene Ther 2007, 7:229-238.
3. Xu Z.L., Mizuguchi H., Sakurai F., Koizumi N., Hosono T., Kawabata K., et al. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev 2005, 57:781-802.
4. Sakurai F., Nakamura S.I., Akitomo K., Shibata H., Terao K., Kawabata K., et al. Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates. Gene Ther 2009, 16:297-302.
5. Kurachi S., Koizumi N., Tashiro K., Sakurai H., Sakurai F., Kawabata K., et al. Modification of pIX or hexon based on fiberless Ad vectors is not effective for targeted Ad vectors. J Control Release 2008, 127:88-95.
6. Suzuki T., Sakurai F., Nakamura S., Kouyama E., Kawabata K., Kondoh M., et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 2008, 16:1719-1726.
7. Mizuguchi H., Koizumi N., Hosono T., Utoguchi N., Watanabe Y., Kay M.A., et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001, 8:730-735.
8. Mizuguchi H., Koizumi N., Hosono T., Ishii-Watabe A., Uchida E., Utoguchi N., et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 2002, 9:769-776.
9. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 72:9706-9713.
10. Okada N., Saito T., Masunaga Y., Tsukada Y., Nakagawa S., Mizuguchi H., et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001, 61:7913-7919.
11. Katayama K., Wada K., Nakajima A., Mizuguchi H., Hayakawa T., Nakagawa S., et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003, 124:1315-1324.
12. Okada Y., Okada N., Mizuguchi H., Hayakawa T., Mayumi T., Mizuno N. An investigation of adverse effects caused by the injection of high-dose TNFalpha-expressing adenovirus vector into established murine melanoma. Gene Ther 2003, 10:700-705.
13. Mizuguchi H., Kay M.A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998, 9:2577-2583.
14. Mizuguchi H., Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999, 10:2013-2017.
15. Kanegae Y., Makimura M., Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994, 47:157-166.
16. Okabe M., Ikawa M., Kominami K., Nakanishi T., Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett 1997, 407:313-319.
17. Nakanishi T., Nishikawa J., Hiromori Y., Yokoyama H., Koyanagi M., Takasuga S., et al. Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol 2005, 19:2502-2516.
18. Tanaka S., Kunath T., Hadjantonakis A.K., Nagy A., Rossant J. Promotion of trophoblast stem cell proliferation by FGF4. Science 1998, 282:2072-2075.
19. Yan J., Tanaka S., Oda M., Makino T., Ohgane J., Shiota K. Retinoic acid promotes differentiation of trophoblast stem cells to a giant cell fate. Dev Biol 2001, 235:422-432.
20. Barr D., Tubb J., Ferguson D., Scaria A., Lieber A., Wilson C., et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995, 2:151-155.
21. Greig J.A., Buckley S.M., Waddington S.N., Parker A.L., Bhella D., Pink R., et al. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther 2009, 17:1683-1691.
22. Vellinga J., de Vrij J., Myhre S., Uil T., Martineau P., Lindholm L., et al. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther 2007, 14:664-670.
23. Nicklin S.A., White S.J., Watkins S.J., Hawkins R.E., Baker A.H. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000, 102:231-237.
24. Nicklin S.A., Von Seggern D.J., Work L.M., Pek D.C., Dominiczak A.F., Nemerow G.R., et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001, 4:534-542.
25. Xia H., Anderson B., Mao Q., Davidson B.L. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000, 74:11359-11366.
26. Work L.M., Nicklin S.A., Brain N.J., Dishart K.L., Von Seggern D.J., Hallek M., et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004, 9:198-208.
27. Denby L., Work L.M., Seggern D.J., Wu E., McVey J.H., Nicklin S.A., et al. Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol Ther 2007, 15:1647-1654.
28. Diaconu I., Denby L., Pesonen S., Cerullo V., Bauerschmitz G.J., Guse K., et al. Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. Hum Gene Ther 2009, 20:611-620.
29. Poulin K.L., Lanthier R.M., Smith A.C., Christou C., Risco Quiroz M., Powell K.L., et al. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010, 84:10074-10086.
30. Schatzlein A.G. Targeting of synthetic gene delivery systems. J Biomed Biotechnol 2003, 2003:149-158.
31. Wickham T.J., Tzeng E., Shears L.L., Roelvink P.W., Li Y., Lee G.M., et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997, 71:8221-8229.
32. Hidaka C., Milano E., Leopold P.L., Bergelson J.M., Hackett N.R., Finberg R.W., et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999, 103:579-587.
33. Havenga M.J., Lemckert A.A., Grimbergen J.M., Vogels R., Huisman L.G., Valerio D., et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 2001, 75:3335-3342.
34. Rea D., Havenga M.J., van Den Assem M., Sutmuller R.P., Lemckert A., Hoeben R.C., et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001, 166:5236-5244.
35. Gall J., Kass-Eisler A., Leinwand L., Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996, 70:2116-2123.
36. Stevenson S.C., Rollence M., Marshall-Neff J., McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997, 71:4782-4790.
37. Chillon M., Bosch A., Zabner J., Law L., Armentano D., Welsh M.J., et al. Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. J Virol 1999, 73:2537-2540.
38. Goossens P.H., Vogels R., Pieterman E., Havenga M.J., Bout A., Breedveld F.C., et al. The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis Rheum 2001, 44:48-52.
39. Stecher H., Shayakhmetov D.M., Stamatoyannopoulos G., Lieber A. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol Ther 2001, 4:36-44.
40. Cashman S.M., Morris D.J., Kumar-Singh R. Adenovirus type 5 p.eudotyped with adenovirus type 37 fiber uses sialic acid as a cellular receptor. Virology 2004, 324:129-139.
41. Mercier G.T., Campbell J.A., Chappell J.D., Stehle T., Dermody T.S., Barry M.A. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci U S A 2004, 101:6188-6193.
42. Hsu C., Boysen M., Gritton L.D., Frosst P.D., Nemerow G.R., Von Seggern D.J. In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity. Virology 2005, 332:1-7.
43. Katz A.B., Keswani S.G., Habli M., Lim F.Y., Zoltick P.W., Midrio P., et al. Placental gene transfer: transgene screening in mice for trophic effects on the placenta. Am J Obstet Gynecol 2009, 201(499):e1-8.
44. Heikkila A., Hiltunen M.O., Turunen M.P., Keski-Nisula L., Turunen A.M., Rasanen H., et al. Angiographically guided utero-placental gene transfer in rabbits with adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine complexes. Gene Ther 2001, 8:784-788.
45. Xing A., Boileau P., Cauzac M., Challier J.C., Girard J., Hauguel-de Mouzon S. Comparative in vivo approaches for selective adenovirus-mediated gene delivery to the placenta. Hum Gene Ther 2000, 11:167-177.
46. Woo Y.J., Raju G.P., Swain J.L., Richmond M.E., Gardner T.J., Balice-Gordon R.J. In utero cardiac gene transfer via intraplacental delivery of recombinant adenovirus. Circulation 1997, 96:3561-3569.
47. Wolfgang M.J., Eisele S.G., Browne M.A., Schotzko M.L., Garthwaite M.A., Durning M., et al. Rhesus monkey placental transgene expression after lentiviral gene transfer into preimplantation embryos. Proc Natl Acad Sci U S A 2001, 98:10728-10732.
48. Okada Y., Ueshin Y., Isotani A., Saito-Fujita T., Nakashima H., Kimura K., et al. Complementation of placental defects and embryonic lethality by trophoblast-specific lentiviral gene transfer. Nat Biotechnol 2007, 25:233-237.
49. Alba R., Bradshaw A.C., Coughlan L., Denby L., McDonald R.A., Waddington S.N., et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010, 116:2656-2664.
50. Sakurai H., Tashiro K., Kawabata K., Yamaguchi T., Sakurai F., Nakagawa S., et al. Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J Immunol 2008, 180:4931-4938.
51. Matsui H., Sakurai F., Kurachi S., Tashiro K., Sugio K., Kawabata K., et al. Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene Ther 2009, 16:1050-1057.
52. Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J 1998, 330(Pt 1):163-168.